ANEBULO PHARMACEUTICALS, INC. Liabilities, Fair Value Adjustment
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Liabilities, Fair Value Adjustment of $26.63 million for the 12-month period ending 2021-06-30, per its 10-K filed 2022-09-09.
Discontinued › Notes
us-gaap:LiabilitiesFairValueAdjustment · last filed 2022-09-09
- ANEBULO PHARMACEUTICALS, INC. liabilities, fair value adjustment for fiscal 2021 was $26.63M.
| Period end | Liabilities, Fair Value Adjustment 12 month |
|---|---|
| 2021-06-30 | $26.63M 10-K · filed 2022-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |